Previous close | 5.50 |
Open | 5.50 |
Bid | 8.00 |
Ask | 10.70 |
Strike | 45.00 |
Expiry date | 2024-08-16 |
Day's range | 5.50 - 5.50 |
Contract range | N/A |
Volume | |
Open interest | 18 |
Key Insights 10x Genomics to hold its Annual General Meeting on 11th of June Total pay for CEO Serge Saxonov includes...
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of its Xenium Prime 5K Pan-Tissue and Pathways panel. The new assay features an enhanced chemistry to increase plex by an order of magnitude while delivering excellent per-gene sensitivity, improved specificity and spatial fidelity, integrated multimodal cell segmentation, and industry-leading speed and throughput.
Review 10x Genomics' (TXG) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.